Loading...
  • aggressive cancers
  • The breakthrough we've had in the last few months is that we see image signatures that distinguish aggressive cancers from less aggressive ones," said Anant Madabhushi, associate professor of biomedical engineering at Rutgers and a member of The Cancer Institute of New Jersey (CINJ). (blogspot.com)
  • Radiopharmaceuticals
  • Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval. (urotoday.com)
  • molecular
  • 5) Generation of engineered mouse models and mouse xenografts to be utilized in the investigation of molecular phenotypes of prostate cancer as well as in preclinical studies. (frontiersin.org)
  • scan
  • The second study evaluated the agreement between 96 Axumin and C11 choline (an approved PET scan imaging test) scans in patients with median PSA values of 1.44 ng/mL. (fda.gov)
  • The second study evaluated the agreement between 96 fluciclovine F-18 and choline C-11 (an approved PET scan imaging test) scans in patients with median PSA values of 1.44 ng/mL. (ascopost.com)
  • distinguishing low-grade
  • In a presentation next month at the world's premier medical image analysis conference, Rutgers biomedical engineers will report that they achieved over 90% accuracy in distinguishing low-grade from high-grade prostate cancers by running computer analyses of the images and spectra made on 19 patients in an early research study. (blogspot.com)